Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...